EPIZYME, INC. This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -1.02% | 21.48B | |
| -18.14% | 20.82B | |
| -6.87% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
